Daily intraperitoneal dosing (2.5–10 mg/kg) significantly suppressed tumor growth, with efficacy comparable to standard-of-care therapies—paclitaxel in TNBC, gemcitabine in PDAC—and notably superior to trastuzumab in Her2-positive breast cancers. The gene discussed is ERBB2; the disease is neoplasm.